Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TSVT

TSVT - 2seventy bio, Inc. Stock Price, Fair Value and News

3.95USD-0.14 (-3.42%)Market Closed

Market Summary

TSVT
USD3.95-0.14
Market Closed
-3.42%

TSVT Stock Price

View Fullscreen

TSVT RSI Chart

TSVT Valuation

Market Cap

203.1M

Price/Earnings (Trailing)

-0.91

Price/Sales (Trailing)

2.85

EV/EBITDA

-0.69

Price/Free Cashflow

-1.21

TSVT Price/Sales (Trailing)

TSVT Profitability

EBT Margin

-313.51%

Return on Equity

-107.61%

Return on Assets

-43.68%

Free Cashflow Yield

-82.77%

TSVT Fundamentals

TSVT Revenue

Revenue (TTM)

71.2M

Rev. Growth (Yr)

-70.12%

Rev. Growth (Qtr)

16.39%

TSVT Earnings

Earnings (TTM)

-223.2M

Earnings Growth (Yr)

-12.02%

Earnings Growth (Qtr)

7.3%

Breaking Down TSVT Revenue

Last 7 days

1.0%

Last 30 days

-18.9%

Last 90 days

-1.5%

Trailing 12 Months

-63.2%

How does TSVT drawdown profile look like?

TSVT Financial Health

Current Ratio

3.52

TSVT Investor Care

Shares Dilution (1Y)

2.40%

Diluted EPS (TTM)

-4.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202471.2M000
2023124.7M147.3M145.9M100.4M
202251.0M57.2M51.4M91.5M
2021199.7M151.3M102.9M54.5M
202000146.2M248.1M
201900044.3M

Tracking the Latest Insider Buys and Sells of 2seventy bio, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
maus marcela v.
acquired
-
-
12,050
-
Jun 10, 2024
wei lin
acquired
-
-
12,050
-
Jun 10, 2024
newton charles w.
acquired
-
-
6,025
-
Jun 10, 2024
torres denice
acquired
-
-
12,050
-
Jun 10, 2024
glickman sarah js
acquired
-
-
12,050
-
Jun 10, 2024
casdin capital, llc
acquired
-
-
6,025
-
Jun 03, 2024
eatwell victoria
sold
-4,880
4.1823
-1,167
chief financial officer
Jun 03, 2024
snow jessica
sold
-2,714
4.1823
-649
see remarks
May 03, 2024
snow jessica
sold
-147
4.91
-30.00
see remarks

1–10 of 50

Which funds bought or sold TSVT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Highlander Capital Management, LLC
reduced
-45.36
-493
1,070
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-8,282
27,018
-%
May 16, 2024
SkyView Investment Advisors, LLC
new
-
54,000
54,000
0.01%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-90.5
-783,111
105,796
-%
May 15, 2024
AMERIPRISE FINANCIAL INC
reduced
-49.88
-69,517
117,368
-%
May 15, 2024
BARCLAYS PLC
added
99.54
536,000
892,000
-%
May 15, 2024
Voya Investment Management LLC
reduced
-73.86
-176,356
85,878
-%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
104,436
517,345
0.01%
May 15, 2024
Engine Capital Management, LP
unchanged
-
1,613,850
7,994,530
1.61%
May 15, 2024
Madison Avenue Partners, LP
added
38.66
5,524,790
13,017,700
2.10%

1–10 of 48

Are Funds Buying or Selling TSVT?

Are funds buying TSVT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TSVT
No. of Funds

Unveiling 2seventy bio, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
4.99%
2,527,672
SC 13G/A
Feb 13, 2024
vanguard group inc
7.87%
3,985,770
SC 13G/A
Feb 12, 2024
morgan stanley
9.4%
4,748,235
SC 13G
Feb 08, 2024
goldman sachs group inc
8.8%
4,471,192
SC 13G
Feb 01, 2024
millennium management llc
4.7%
2,357,072
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
3,911,724
SC 13G/A
Jan 23, 2024
state street corp
1.93%
977,590
SC 13G/A
Nov 09, 2023
wellington management group llp
1.59%
802,967
SC 13G/A
Oct 10, 2023
state street corp
2.12%
1,069,125
SC 13G/A

Recent SEC filings of 2seventy bio, Inc.

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 11, 2024
8-K
Current Report
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading

Peers (Alternatives to 2seventy bio, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

2seventy bio, Inc. News

Latest updates
MarketBeat40 hours ago

2seventy bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Revenue16.4%12,435,00010,684,00012,034,00036,048,00041,621,00056,177,00013,408,00013,482,0008,429,00016,035,00019,257,0007,328,00011,901,00015,167,50018,434,000-
Costs and Expenses-10.0%63,589,00070,620,00090,002,00084,039,00093,334,00083,389,00081,776,00090,454,00099,017,00084,405,00084,495,00095,299,000104,271,000-94,848,000-
  S&GA Expenses-21.9%12,659,00016,201,00013,004,00019,489,00020,720,00018,701,00019,610,00017,278,00023,861,00024,481,00022,996,00021,402,00024,627,000-22,105,000-
  R&D Expenses-14.2%43,931,00051,217,00051,315,00059,980,00068,246,00060,144,00058,155,00064,557,00065,879,00050,223,00061,131,00063,692,00077,571,000-72,253,000-
EBITDA Margin-44.9%-2.99-2.06-1.19-1.16-1.65-2.65-5.44-4.70-5.38-5.06-1.04-0.71-0.54-0.43-2.11-
Interest Expenses-----------------
Income Taxes-----------------
Earnings Before Taxes7.3%-52,673,000-56,822,000-71,638,000-42,089,000-47,021,000-23,143,000-67,879,000-77,420,000-85,711,000-60,975,000-60,001,000-84,042,000-87,196,000--72,075,000-
EBT Margin-44.7%-3.14-2.17-1.26-1.22-1.73-2.78-5.69-4.97-5.70-5.36-1.17-0.79-0.60-0.48-2.19-
Net Income7.3%-52,673,000-56,822,000-71,638,000-42,089,000-47,021,000-23,143,000-67,879,000-77,420,000-85,711,000-60,976,000-60,001,000-84,040,000-87,196,000-76,801,000-72,075,000-
Net Income Margin-44.7%-3.14-2.17-1.26-1.22-1.73-2.78-5.69-4.97-5.70-5.36-2.99-2.12-0.67-0.48-2.19-
Free Cashflow34.3%-42,512,000-64,666,000-24,207,000-36,683,000-55,167,000-58,727,000-74,031,000-49,125,000-77,067,000-58,235,000-45,974,000-43,120,000-71,101,000---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32020Q4
Assets-9.6%511565641706742657709787852760193313
  Current Assets-10.5%21323827733439030134938441329225.0025.00
    Cash Equivalents-24.2%57.0075.0090.0096.0019472.00127270271130--
  Net PPE-34.2%38.0058.0061.0061.0059.0056.0047.0039.0035.0035.0034.00144
  Goodwill----12.0012.0012.0012.0012.0012.0012.0012.0013.00
Liabilities-2.1%304310334338341346386408405400251238
  Current Liabilities1.0%60.0060.0068.0067.0077.0080.0080.0099.0010698.0010676.00
Shareholder's Equity-18.7%207255306367401310323379447360-75.00
  Retained Earnings-10.3%-563-511-454-382-340-293-270-202-125-39.49--
  Additional Paid-In Capital0.6%772767762752744607598585575400--
Shares Outstanding1.5%51.0051.0051.0050.0043.0038.0035.0033.0027.0023.0023.0023.00
Float----508---497613---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations34.1%-41,900-63,595-21,512-32,663-49,088-47,593-60,613-46,452-73,482-57,260-43,350-41,495-64,750---
  Share Based Compensation-5.4%4,6844,9539,8007,7409,6669,40512,2079,6899,73914,32311,22911,96817,109---
Cashflow From Investing-54.4%21,83347,89016,054-64,88144,798-8,500-82,29549,79944,7491,014-8,624-3,625-6,351---
Cashflow From Financing52.6%386253-75.00128127,084232175-4,277170,099186,69451,97445,12071,101---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TSVT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Collaborative arrangement revenue$ 4,714$ 29,372
Total revenues12,43541,621
Operating expenses:  
Research and development43,93168,246
Cost of manufacturing for commercial collaboration3,2693,654
Selling, general and administrative12,65920,720
Share of collaboration loss1,2300
Stock-based compensation expense4,2300
Cost of royalty and other revenue0641
Change in fair value of contingent consideration(1,730)73
Total operating expenses63,58993,334
Loss from operations(51,154)(51,713)
Interest income, net2,8612,049
Other income, net6462,643
Loss on assets held for sale(5,026)0
Loss before income taxes(52,673)(47,021)
Income tax (expense) benefit00
Net loss$ (52,673)$ (47,021)
Net loss per share - basic (in dollars per share)$ (1.01)$ (1.08)
Net loss per share - diluted (in dollars per share)$ (1.01)$ (1.08)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)52,071,00043,468,000
Weighted-average number of common shares used in computing net loss per share - diluted (in shares)52,071,00043,468,000
Other comprehensive (loss) income:  
Other comprehensive (loss) income, net of tax benefit (expense) of $0.0 million and $0.0 million for the three months ended March 31, 2024 and 2023, respectively.$ (132)$ 927
Comprehensive loss(52,805)(46,094)
Service revenue  
Revenue:  
Revenue7,72110,826
Royalty and other revenue  
Revenue:  
Revenue$ 0$ 1,423

TSVT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 56,792$ 74,958
Marketable securities124,590142,031
Assets held for sale12,7860
Prepaid expenses6,6977,365
Receivables and other current assets11,97713,411
Total current assets212,842237,765
Property, plant and equipment, net38,23458,150
Marketable securities04,816
Intangible assets, net6,4176,594
Operating lease right-of-use assets215,317219,958
Restricted investments and other non-current assets38,24138,143
Total assets511,051565,426
Current liabilities:  
Accounts payable8,8016,028
Accrued expenses and other current liabilities22,26325,688
Operating lease liability, current portion13,00612,660
Deferred revenue, current portion16,33615,403
Total current liabilities60,40659,779
Deferred revenue, net of current portion2,4503,918
Operating lease liability, net of current portion240,071244,013
Other non-current liabilities6852,416
Total liabilities303,612310,126
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000 shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 200,000 shares authorized, 51,404 and 50,632 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively55
Additional paid-in capital771,660766,716
Accumulated other comprehensive loss(336)(204)
Accumulated deficit(563,890)(511,217)
Total stockholders’ equity207,439255,300
Total liabilities and stockholders’ equity$ 511,051$ 565,426
TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITE2seventybio.com
 INDUSTRYBiotechnology
 EMPLOYEES425

2seventy bio, Inc. Frequently Asked Questions


What is the ticker symbol for 2seventy bio, Inc.? What does TSVT stand for in stocks?

TSVT is the stock ticker symbol of 2seventy bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 2seventy bio, Inc. (TSVT)?

As of Fri Jun 14 2024, market cap of 2seventy bio, Inc. is 203.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers. The fair value of 2seventy bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 2seventy bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TSVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 2seventy bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether TSVT is over valued or under valued. Whether 2seventy bio, Inc. is cheap or expensive depends on the assumptions which impact 2seventy bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSVT.

What is 2seventy bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, TSVT's PE ratio (Price to Earnings) is -0.91 and Price to Sales (PS) ratio is 2.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSVT PE ratio will change depending on the future growth rate expectations of investors.